Every breath matters.
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Background</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Anjelica Gonzalez</td>
<td>Inventor &amp; Co-founder</td>
<td>PHD, MPH, MSED, ‘20 Yale Blavatnik Fellow Biomedical Engineer &amp; Yale Faculty</td>
</tr>
<tr>
<td>Mr. Jamison Langguth</td>
<td>CEO &amp; Co-founder</td>
<td>MPH, MSED, 10 Years Clinops, 2 Years Biotech BD</td>
</tr>
<tr>
<td>Dr. Wally Carlo</td>
<td>Board - Clinical</td>
<td>MD, Neonatologist &amp; Pediatrician</td>
</tr>
<tr>
<td>Dr. Brian Harvey</td>
<td>Board - Regulatory</td>
<td>MD, PHD Ex-FDA &amp; Pfizer, Yale Entrepreneur in Residence</td>
</tr>
<tr>
<td>Confidential</td>
<td>CRO – Product Dev</td>
<td>MS Fixed fee services from design to full scale manufacturing</td>
</tr>
</tbody>
</table>

Aero Therapeutics, Inc
Core Team, Board and CRO Partner
Neonatal Respiratory Distress
All Settings: Full Range of Potential Devices

- Improvised Device
- Full Mechanical Ventilator
- CPAP
- High Flow

Our Device

Copyright © 2021 aero therapeutics
PremieBreathe Respirator

Intellectual Property:
PORTABLE AND COMPACT SYSTEM FOR DELIVERY OF HUMIDIFIED HIGH FLOW NASAL CANNULA (HHFNC) THERAPY IN NEONATES AND INFANTS” Docket Number PCT Filed 23Aug2019: 047162-5227-P3US

Copyright © 2021 aero therapeutics
• JLABs San Diego residency began in January.

• We met with FDA in March about our proposed pathway and received an explicit roadmap towards approval in the US.

• We have a clear pathway to a commercial product in the US.
Focused US Competition

Incumbent to beat

PremieBreathe

Vapotherm HVNI

Humidified

Warmed

Mixed O2

Price (USD)

~$8,667

$1K – $3K

Estimated COGS

$4,000 – $6,000

$300 – $1,000

Copyright © 2021 aero therapeutics
**Key Revenue Channels**

**Compete on price**
We can build these devices cheaper and still sell for a profitable margin.

**Consumables**
We are exploring: nasal cannulas, UV, wicking, filters, & heavy metals.

**Bundling opportunities**
There have been great strides in O2 concentrators but O2 mixers have not innovated for these to flourish.

**Risk sharing potential**
Down the road we could offer the hardware cheaper than competitors and capture some of the outcomes value.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Selection and Onboard CRO</td>
<td>Due June 30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wrap Design: Review of Files</td>
<td></td>
<td>Due July 31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aim 1 Testing: Upgraded Design</td>
<td></td>
<td></td>
<td>Due October 06</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aim 2 Testing: Performance and Safety</td>
<td></td>
<td></td>
<td></td>
<td>Due December 05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aim 3: Complete Remaining Bench-level Tests per FDA Feedback</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Submit 510k</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secure Manufacturer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manufacture &gt; 1,000 Devices</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Build Early Support Team</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Yale OCR**
- **Anjelica Gonzalez**
- **CRO: Confidential**
- **Aero Project Management Team**
- **Manufacturing Partner**

**510k FDA Submission**

**Milestone: FDA Approval**

**Due April 30**

**Due July 31st**

Copyright © 2021 aero therapeutics
Accelerators, Awards, Funding & Partners
Raised $280,000 as of 05 May 2021
Exit – Acquisition

Johnson & Johnson

ResMed

Philips Healthcare

Siemens

Medtronic

GE Healthcare
There is a sizable market for this kind of technology that is growing.
Unlisted Pulm CPT Code 94662: $136.32
CPAP designated CPT Code 94660: $186.38
E&M APC Code 5041: $734

• Encourage hospitals to use on an unlisted pulmonary service bundled into the Critical Care Evaluation & Management (E&M) CPT code for a higher reimbursement.

• This mirrors a CPAP strategy, where the use of a CPAP is bundled in the same APC.
# Post-Approval Timeline

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Submit 510k</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Build Clinical Data Team</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seek IRB approvals for clinical data collection at H &amp; Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Data Collection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Publication Goal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ongoing Sales Efforts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Clinical Partnerships**

- Anjelica Gonzalez
- Aero Project Management Team

**Data Collection Due Jan 31st**

**Publication Submission Due March 31st**

ENTRY

- FDA Approval

Due June 30th

Due July 31st

Ongoing

Copyright © 2021 aero therapeutics